Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	183.93	56.86	67.21
Cash & Short-Term Investments	183.93	56.86	67.21
Cash Growth	173.67%	-15.40%	-
Prepaid Expenses	3.47	1.65	1.24
Other Current Assets	1.2	1.3	-
Total Current Assets	188.6	59.8	68.44
Property, Plant & Equipment	0.71	1.01	1.8
Long-Term Deferred Charges	3.69	1.39	-
Other Long-Term Assets	6.96	5.97	4.33
Total Assets	199.95	68.18	74.58
Accounts Payable	8.36	5.4	5.82
Accrued Expenses	29.73	17.01	19.44
Current Portion of Leases	0.49	0.56	0.72
Current Income Taxes Payable	-	0.3	-
Total Current Liabilities	39.11	23.26	25.97
Long-Term Debt	-	20.3	-
Long-Term Leases	0.01	0.26	0.81
Total Liabilities	39.12	43.82	26.78
Common Stock	0	0	0
Additional Paid-In Capital	7.29	4.64	1.03
Retained Earnings	-296.18	-230.4	-193.28
Comprensive Income & Other	0.1	0.04	-0.04
Total Common Equity	-288.78	-225.72	-192.29
Shareholders' Equity	160.83	24.37	47.8
Total Liabilities & Equity	199.95	68.18	74.58
Total Debt	0.51	21.11	1.53
Net Cash (Debt)	183.42	35.74	65.68
Net Cash Growth	179.26%	-45.58%	-
Net Cash Per Share	13.63	2.69	5.07
Filing Date Shares Outstanding	13.71	13.69	13.45
Total Common Shares Outstanding	13.71	13.69	13.45
Working Capital	149.49	36.55	42.48
Book Value Per Share	-21.07	-16.49	-14.29
Tangible Book Value	-288.78	-225.72	-192.29
Tangible Book Value Per Share	-21.07	-16.49	-14.29

Source: S&P Capital IQ. Standard template. Financial Sources.